BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking an L-phenylalanine and L-arginine metabolic enzyme for cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; chronic lymphocytic leukemia (CLL) Inhibiting IL4I1, which metabolizes L-phenylalanine and L-arginine, could treat CLL, glioblastoma multiforme and glioma. Computational analyses of gene expression data and published studies identified a pan-tissue...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...with differences in outcomes in adults Lunenfeld-Tanenbaum Research Institute e22525 TPR-TrkA; EML1-TrkB; KANK1-TrkB; EML4-TrkC; ETV6-TrkC;EEF1G-ROS1; GOPC-ROS1...
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Mar 15, 2019
Emerging Company Profile

Neurogene: Genes over ERT for monogenic CNS diseases

Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn't been explored. Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by autosomal recessive AGA mutations...
BioCentury | Apr 25, 2016

Endangered TIGER?

...result in higher concentrations of metabolites associated with hyperglycemia and QT prolongation.At the bottom of Fig...
...flat across the steady-state concentrations of rociletinib.In contrast, the box plot at the bottom of Fig...
...3 or 4 hyperglycemia increased along with increasing concentrations of the M502 metabolite. Similarly, in Fig...
BioCentury | Dec 5, 2013
Distillery Techniques

Technology: Disease models

...stromal cell infiltration. In the model, induced expression of a fusion gene containing Golgi-associated PDZ and coiled-coil motif containing (GOPC; FIG...
BioCentury | Nov 19, 2007

Ebb & Flow

...toward the middle of its range despite the aftermarket difficulties of hedge fund peers Fortress (FIG...
Items per page:
1 - 7 of 7